Cellectis: operations financed until 2026
With the completion of the additional $140 million investment from the pharmaceutical giant, the biotech company had some $143 million in cash on March 31.
The company believes that this capital will be sufficient to finance its operations until 2026.
The genome-editing specialist - which seeks to develop potential therapies for the treatment of serious diseases - reported adjusted consolidated net income attributable to shareholders of $6.5 million (or $0.09 per share) for the first three months of 2024, compared with a net loss of $28.1 million (or a loss of $0.55 per share) for the first three months of 2023.
Consolidated sales and other operating income amounted to $6.5 million for the quarter, compared with $3.6 million for the same period in 2023.
Following this publication, Cellectis shares were little changed (-0.4%) on Wednesday morning on the Paris Bourse. The stock has lost more than 11% since the start of the year, but is up 37% over the last 12 months.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction